Cipla Board Approves Re-appointment of P R Ramesh as Independent Director for Second Term

1 min read     Updated on 23 Jan 2026, 02:32 PM
scanx
Reviewed by
Naman SScanX News Team
Overview

Cipla Limited's Board has approved Mr P R Ramesh's re-appointment as Independent Director for a second five-year term from July 2026 to June 2031, subject to shareholder approval. The decision was made during a board meeting on January 23, 2026. Mr Ramesh, who has served as Independent Director since July 2021 and currently chairs the Audit Committee, brings over 45 years of experience and serves on boards of several leading companies including Air India, L&T, and Nestlé India.

30704544

*this image is generated using AI for illustrative purposes only.

Cipla Limited's Board of Directors has approved the re-appointment of Mr P R Ramesh as Independent Director for a second consecutive five-year term. The decision was taken during a board meeting held on January 23, 2026, demonstrating the company's confidence in his continued leadership and expertise.

Re-appointment Details

The board meeting, which commenced at 11:00 a.m. (IST) and concluded at 2:00 p.m. (IST), approved Mr Ramesh's re-appointment subject to shareholder approval. The appointment will be effective for five consecutive years from July 1, 2026, to June 30, 2031.

Parameter: Details
Director Name: Mr P R Ramesh
DIN: 01915274
Term Duration: 5 years
Commencement Date: July 1, 2026
End Date: June 30, 2031
Status: Subject to shareholder approval

Professional Background and Qualifications

Mr P R Ramesh brings extensive experience to Cipla's board, with over 45 years of professional expertise across multiple sectors. He graduated in Commerce from Osmania University, Hyderabad, and is a Fellow Member of the Institute of Chartered Accountants of India (ICAI).

His distinguished career includes his tenure as Director of Deloitte & Touche Assurance & Enterprise Risk Services India Private Limited, from which he retired on March 31, 2020. During his time at Deloitte, he served as a member of both the Deloitte Global Board and Deloitte Asia Pacific Board, gaining valuable international experience.

Current Role and Responsibilities

Mr Ramesh has been serving as an Independent Director on Cipla's Board since July 1, 2021, and currently chairs the Audit Committee. His expertise spans multiple industry sectors including:

  • Manufacturing
  • Banking and financial services
  • Technology, media, and telecommunications
  • Energy and resources
  • Consumer business sectors

Other Board Positions

Mr Ramesh serves on the boards of several leading companies, demonstrating his expertise and reputation in corporate governance:

  • Air India
  • Larsen & Toubro (L&T)
  • Nestlé India
  • Crompton Greaves Consumer Electricals
  • ITC Hotels

Regulatory Compliance

The re-appointment has been disclosed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that Mr Ramesh is not debarred from holding the office of director by virtue of any SEBI order or any other authority. Additionally, he has no relationships with other directors of the company, ensuring independence in his role.

Historical Stock Returns for Cipla

1 Day5 Days1 Month6 Months1 Year5 Years
-0.14%-6.03%-12.49%-10.88%-9.51%+56.93%

Cipla Co-CEO Expects Upcoming Launches to Cushion Revlimid Revenue Impact

0 min read     Updated on 23 Jan 2026, 01:56 PM
scanx
Reviewed by
Suketu GScanX News Team
Overview

Cipla's Co-CEO has announced that upcoming product launches are expected to help offset revenue challenges related to Revlimid. This strategic communication reflects the company's proactive approach to portfolio management and revenue diversification in the oncology segment.

30702403

*this image is generated using AI for illustrative purposes only.

Cipla 's Co-CEO has stated that the pharmaceutical company's upcoming product launches are expected to help cushion revenue impact from Revlimid, signaling the company's strategic approach to managing its oncology portfolio.

Strategic Product Portfolio Management

The Co-CEO's comments highlight Cipla's proactive stance in addressing potential revenue fluctuations through its pipeline of new product launches. This approach demonstrates the company's focus on maintaining revenue stability through diversified product offerings.

Revlimid Market Dynamics

Revlimid, a significant oncology medication, represents an important component of Cipla's pharmaceutical portfolio. The Co-CEO's acknowledgment of the need to cushion revenue impact suggests the company is navigating market changes affecting this particular product segment.

Pipeline Strategy

The emphasis on upcoming launches indicates Cipla's commitment to continuous product development and market introduction strategies. This approach reflects the pharmaceutical industry's standard practice of maintaining robust pipelines to ensure sustained revenue growth and market presence.

Historical Stock Returns for Cipla

1 Day5 Days1 Month6 Months1 Year5 Years
-0.14%-6.03%-12.49%-10.88%-9.51%+56.93%

More News on Cipla

1 Year Returns:-9.51%